Veru (VERU) Competitors

Veru (NASDAQ:VERU) and MEDIFAST (NYSE:MED) are both small-cap personal products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.

Does the media refer more to VERU or MED?

In the previous week, Veru and Veru both had 1 articles in the media. Veru's average media sentiment score of 0.58 beat MEDIFAST's score of 0.50 indicating that Veru is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MEDIFAST	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders and institutionals have more ownership in VERU or MED?

47.2% of Veru shares are held by institutional investors. Comparatively, 95.5% of MEDIFAST shares are held by institutional investors. 15.2% of Veru shares are held by insiders. Comparatively, 2.9% of MEDIFAST shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has preferable earnings & valuation, VERU or MED?

MEDIFAST has higher revenue and earnings than Veru. Veru is trading at a lower price-to-earnings ratio than MEDIFAST, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	3.12	-$37.80M	-$2.20	-1.64
MEDIFAST	$602.46M	0.26	$2.09M	$0.32	44.62

Which has more volatility & risk, VERU or MED?

Veru has a beta of -0.72, suggesting that its share price is 172% less volatile than the S&P 500. Comparatively, MEDIFAST has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500.

Do analysts recommend VERU or MED?

Veru currently has a consensus price target of $33.33, indicating a potential upside of 825.93%. MEDIFAST has a consensus price target of $16.50, indicating a potential upside of 15.56%. Given Veru's stronger consensus rating and higher possible upside, equities analysts plainly believe Veru is more favorable than MEDIFAST.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
MEDIFAST	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Is VERU or MED more profitable?

MEDIFAST has a net margin of 0.76% compared to Veru's net margin of 0.00%. MEDIFAST's return on equity of 2.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-143.24%	-85.22%
MEDIFAST	0.76%	2.00%	1.50%

Summary

MEDIFAST beats Veru on 9 of the 15 factors compared between the two stocks.